Sophie Paczesny, MD, PhD

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.

Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.

Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.

Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.

Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.

Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.

Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.

Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.

Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.

Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.

Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.

Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.

Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.

Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.

Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.

Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.

Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.

Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.

Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.

Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.

Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.

Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.

All panelists provide their final thoughts on the current landscape and future directions in graft-vs-host disease (GVHD).

Sophie Paczesny, MD, PhD, provides an overview of the drug ibrutinib for use in steroid-refractory chronic graft-vs-host disease (GVHD). She elicits thoughts from the panelists on how they envision this drug being used.

Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.

Dr Chen provides an overview of the prevalence of steroid refractory GVHD and leads a discussion on how steroid refractory GVHD is defined.

Dr Cutler leads a discussion on the approach to management of chronic GVHD and whether complete response is a realistic end point.